Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease

Next Previous
X
Search
Trial Profile

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betibeglogene-autotemcel (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors bluebird bio

    • Most Recent Events

    • 10 Dec 2024 Status changed from recruiting to active, no longer recruiting.
    • 05 Nov 2024 According to a bluebird bio media release, updated follow-up data and analysis of early predictors and response to lovotibeglogene autotemcel (lovo-cel) in patients from HGB-206 and HGB-210 studies, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will take place December 7-10, 2024 at the San Diego Convention Center and online.
    • 26 Mar 2024 According to a bluebird bio media release, enrollment is ongoing for patients under the age of 12. The Company anticipates enrollment to be complete in Q4 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top